Form 4: RTW Investments Settles Rocket Pharma Equity Swaps

RTW Investments, LP and Roderick Wong reported the settlement of several equity swaps in Rocket Pharmaceuticals, resulting in no net change to their aggregate beneficial ownership.

Summary

• RTW Investments, LP and Roderick Wong, a director and 10% owner of Rocket Pharmaceuticals, Inc. (RCKT), filed a Form 4 detailing changes in beneficial ownership.
• The filing reports the expiration and settlement of multiple equity swap agreements on September 19, 2025.
• These settlements involved the acquisition and subsequent disposition of common stock, totaling 1,100,000 shares (1,000,000 + 41,000 + 59,000).
• The acquisition prices for these shares ranged from $17.8112 to $40.0324, while the disposition price was consistently $3.105.
• Crucially, after these transactions, the aggregate amount of Common Stock beneficially owned by the Reporting Persons did not change.
• Roderick Wong also directly holds 47,667 restricted stock units (RSUs) that convert to common stock on a one-for-one basis and will vest in full on June 18, 2026.

Sentiment

Score: 5

Explanation: The filing reports the expected settlement of equity swaps, resulting in no net change to beneficial ownership. This is a neutral event, reflecting the execution of prior agreements rather than new strategic moves or significant financial performance indicators.

Positives

• The settlement of previously reported equity swaps indicates the fulfillment of contractual obligations.
• No net change in the aggregate beneficial ownership by RTW Investments and Roderick Wong suggests stability in their long-term holding strategy.

Negatives

• The filing does not introduce any new positive developments or strategic initiatives for Rocket Pharmaceuticals.

Future Outlook

Roderick Wong's 47,667 restricted stock units are scheduled to vest in full on June 18, 2026.

Management Comments

• After the transaction reported herein, the amount of Common Stock of the Issuer beneficially owned in the aggregate by the Reporting Persons did not change.
• Each Reporting Person disclaims beneficial ownership in the securities reported on this Form 4 except to the extent of its or his pecuniary interest, if any, therein, and this report shall not be deemed to be an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.

Industry Context

This Form 4 is specific to insider transactions and does not provide broader industry context or trends.

Related Party Transactions

• The transactions involve RTW Investments, LP, which manages the RTW Funds, and Roderick Wong, who is the Managing Partner and Chief Investment Officer of RTW Investments and also a director and Chairman of Rocket Pharmaceuticals' Board of Directors. These are considered related party transactions due to the interlocking relationships.

Stakeholder Impact

• Shareholders: The filing indicates no net change in the aggregate beneficial ownership of a significant 10% owner and director, which might be viewed as a stable signal regarding their long-term commitment, despite the mechanical nature of the swap settlements.

Next Steps

• Roderick Wong's 47,667 restricted stock units are scheduled to vest in full on June 18, 2026.

Key Dates

Recommendation

This Form 4 reports the expected settlement of previously disclosed equity swaps by a significant insider and 10% owner, RTW Investments, LP, and its managing partner, Roderick Wong. The key takeaway is that these transactions resulted in no net change to their aggregate beneficial ownership in Rocket Pharmaceuticals. While the reported acquisition and disposition prices for the common stock involved in the swap settlement show a significant difference, this is part of the swap's mechanics and does not reflect new market buying or selling decisions by the reporting persons. The filing primarily confirms the execution of prior contractual obligations and does not introduce new information that would fundamentally alter the investment thesis for Rocket Pharmaceuticals. Therefore, a 'hold' recommendation is appropriate as there's no new catalyst for a 'buy' or 'sell' decision based solely on this filing.

Keywords

Rocket Pharmaceuticals, RCKT, RTW Investments, Roderick Wong, SEC Form 4, Beneficial Ownership, Equity Swap, Restricted Stock Units, Insider Trading, Biotechnology, Pharmaceuticals